Safety of fentanyl initiation according to past opioid exposure among patients newly prescribed fentanyl patches

CMAJ

Volumn 188, Issue 9, 2016, Pages 648-653

  Friesen, Kevin J ^a   Woelk, Cornelius ^a   Bugden, Shawn ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CODEINE; FENTANYL; LONG ACTING DRUG; MORPHINE; OPIATE; OXYCODONE; PARACETAMOL; SHORT ACTING DRUG; NARCOTIC ANALGESIC AGENT;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANADA; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG DOSE TITRATION; DRUG EXPOSURE; DRUG FORMULATION; DRUG INDICATION; DRUG MEGADOSE; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOOD AND DRUG ADMINISTRATION; HIGH RISK PATIENT; HOSPITAL ADMISSION; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; SENSITIVITY ANALYSIS; SEX DIFFERENCE; TRANSDERMAL PATCH; TREATMENT DURATION; TREND STUDY; UNSPECIFIED SIDE EFFECT; VERY ELDERLY; ANALGESIA; CUTANEOUS DRUG ADMINISTRATION; MANITOBA; MIDDLE AGED; PAIN MEASUREMENT; PATIENT SAFETY; PROCEDURES;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; FEMALE; FENTANYL; HUMANS; MALE; MANITOBA; MIDDLE AGED; PAIN MANAGEMENT; PAIN MEASUREMENT; PATIENT SAFETY;

EID: 84974676233     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.150961     Document Type: Article

References (29)

1. Skaer TL. Dosing considerations with transdermal formulations of fentanyl and buprenorphine for the treatment of cancer pain. J Pain Res 2014;7:495-503.
2. DuragesicMAT [product monograph]. In: Compendium of Pharmaceuticals and Specialties. Toronto: Canadian Pharmacists Association; 2014.
3. Tassinari D, Sartori S, Tamburini E, et al. Transdermal fentanyl as a front-line approach to moderate-severe pain: a meta-analy-sis of randomized clinical trials. J Palliat Care 2009;25:172-80.
4. Ripamonti C, Fagnoni E, Campa T, et al. Is the use of transder-mal fentanyl inappropriate according to the WHO guidelines and the EAPC recommendations? A study of cancer patients in Italy. Support Care Cancer 2006;14:400-7.
5. Fischer B, Jones W, Krahn M, et al. Differences and over-time changes in levels of prescription opioid analgesic dispensing from retail pharmacies in Canada, 2005-2010. Pharmacoepidemiol Drug Saf 2011;20:1269-77.
6. National Prescription Drug Utilization Information System. Utilization of prescription opioids in Canada's public drug plans, 2006/07 to 2012/13. Ottawa: Patented Medicine Prices Review Board; 2014.
7. Gomes T, Mamdani MM, Paterson JM, et al. Trends in high-dose opioid prescribing in Canada. Can Fam Physician 2014;60:826-32.
8. Firestone M, Goldman B, Fischer B. Fentanyl use among street drug users in Toronto, Canada: behavioural dynamics and public health implications. Int J Drug Policy 2009;20:90-2.
9. Deaths involving fentanyl in Canada, 2009-2014. In: Bulletin CCENDU. Ottawa: Canadian Centre on Substance Abuse; 2015. Available: www.ccsa.ca/Resource%20Library/CCSA-CCENDU-Fentanyl-Deaths-Canada-Bulletin-2015-en.pdf (accessed 2016 Jan. 18).
10. Dosa DM, Dore DD, Mor V, et al. Frequency of long-acting opioid analgesic initiation in opioid-naive nursing home residents. J Pain Symptom Manage 2009;38:515-21.
11. Duragesic (fentanyl transdermal system). Silver Spring (MD): US Food and Drug Administration; 2005. Available: www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHuman MedicalProducts/ucm151138.htm (accessed 2015 Aug. 14).
12. FDA issues second safety warning on fentanyl skin patch: deaths and serious injuries from improper use. Silver Spring (MD): US Food and Drug Administration; 2007. Available: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm109046. htm (accessed 2015 Aug. 14).
13. Important safety information on Duragesic (fentanyl transder-mal system). Ottawa: Health Canada; 2005. Available: healthy canadians.gc.ca/recall-alert-rappel-avis/hc-sc/2005/14319a-eng.php (accessed 2015 Aug. 14).
14. Analysis of international fndings from incidents involving fen-tanyl transdermal patches. ISMP Canada Safety Bulletin 2009;9(10):1-4. Available: www.ismp-canada.org/download/safetyBulletins/ISMPCSB2009-10-AnalysisOfInternational FindingsFromIncidentsInvolvingFentanylTrans dermal.pdf (accessed 2015 Aug. 1).
15. Drug interaction incident with HIV post-exposure prophylaxis. ISMP Canada Safety Bulletin 2008;8(3):1-2. Available: www. ismp-canada.org/download/safetyBulletins/ISMPCSB2008-03HIVPEP.pdf (accessed 2015 Aug. 1).
16. Fentanyl patch linked to another death in Canada. ISMP Canada Safety Bulletin 2007;7(5):1-2. Available: www.ismp-canada.org/download/safetyBulletins/ISMPCSB2007-05Fentanyl.pdf (accessed 2015 Aug. 1).
17. Transdermal fentanyl: a misunderstood dosage form. ISMP Canada Safety Bulletin 2006;6(5):1-4. Available: www.ismp-canada. org/download/safetyBulletins/ISMPCSB2006-05Fentanyl.pdf (accessed 2015 Aug. 1).
18. McMorran M, Longo M. Fentanyl transdermal patch and fatal adverse reactions. Can Adverse Reaction Newsl [Health Canada] 2008;18(3):1-2. Available: www.hc-sc.gc.ca/dhp-mps/alt- formats/pdf/medeff/bulletin/carn-bcei-v18n3-eng.pdf (accessed 2015 Aug. 1).
19. Wichman K, David U. Overdose a risk of transdermal patch in diverse settings. Can Pharm J 2005;138:65-6.
20. Greenall J, Koczmara C, Cheng R, et al. Safety issues with fen-tanyl patches require pharmaceutical care. Can J Hosp Pharm 2008;61:57-9.
21. Dhalla IA, Mamdani MM, Sivilotti MLA, et al. Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone. CMAJ 2009;181:891-6.
22. Canadian guideline for safe and effective use of opioids for chronic non-cancer pain. Part B: recommendations for practice. Hamilton: National Opioid Use Guideline Group; 2010. Available: nationalpaincentre.mcmaster.ca/documents/opioid-guideline- part-b-v5-6.pdf (accessed 2015 Aug. 1).
23. Lane ME. The transdermal delivery of fentanyl. Eur J Pharm Biopharm 2013;84:449-55.
24. Moon JM, Chun BJ. Fentanyl intoxication caused by abuse of transdermal fentanyl. J Emerg Med 2011;40:37-40.
25. Martin TL, Woodall KL, McLellan BA. Fentanyl-related deaths in Ontario, Canada: toxicological fndings and circumstances of death in 112 cases (2002-2004). J Anal Toxicol 2006;30:603-10.
26. Garbe E, Jobski K, Schmid U. Utilisation of transdermal fen-tanyl in Germany from 2004 to 2006. Pharmacoepidemiol Drug Saf 2012;21:191-8.
27. Breekveldt-Postma NS, Penning-van Beest FJA, Herings RMC. Utilisation pattern of fentanyl transdermal system in The Netherlands. Pharmacoepidemiol Drug Saf 2005;14:129-34.
28. McEvoy T, Moore J, Generali J. Inpatient prescribing and monitoring of fentanyl transdermal systems: adherence to safety regulations. Hosp Pharm 2014;49:942-9.
29. Sattler ELP, Lee JS, Perri M. Medication (re)fll adherence measures derived from pharmacy claims data in older Americans: a review of the literature. Drugs Aging 2013;30:383-99.